SmartZyme BioPharma
New York, New York, United States
About SmartZyme BioPharma
Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2018)
- Website: smzyme.com
Industries & Categories
Biotechnology, Diabetes, Health Care, Life Science, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/smartzyme-biopharma-2498995 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.